China insurance industry Report Interpretation

Overview

This event note examines the Ministry of Finance’s announced capital support for five centrally controlled Chinese insurers. Goldman Sachs interprets the action as a policy-support signal, assesses the approval path and capital effects, and discusses implications for PICC Group’s solvency, dividends and valuation.

Core views

On 6 September, PICC Group announced plans to issue new A-shares to the Ministry of Finance (MOF) and raise up to Rmb15bn. China Reinsurance Group also announced a planned MOF-funded raise of up to Rmb3bn. The MOF separately announced capital injections into China Life Insurance Group, China Taiping Insurance Group and China Export & Credit Insurance. Total announced support for the five insurers is up to Rmb70bn. Goldman Sachs considers the named institutions and scope broadly consistent with prior press reporting, as all are centrally controlled insurers, and compares the initiative with capital injection into state-owned banks. The firm notes, however, that the Rmb70bn headline amount is much smaller than the Rmb200bn cited in earlier news reports. On its calculation, the announced support equals an average 5.6% of the five companies’ FY25 net assets. Goldman Sachs therefore characterizes the development principally as a signal of central-government support for the industry rather than presenting it as a transformational increase in capital across the group. For PICC Group and China Re, shareholder approval is expected to be sought at extraordinary general meetings likely to occur at the end of September, followed by approval from relevant regulators including the NFRA and CSRC. PICC estimates that, using the average trading price during the 20 trading days before the announcement, it would issue 2.02bn A-shares, equivalent to approximately 4.6% of existing shares outstanding. PICC Group and China Re state that all proceeds will replenish capital and support ongoing operations. PICC says Rmb15bn of additional equity could increase both core and comprehensive solvency capital by 6 percentage points, and it reiterated an intention to maintain a stable and growing dividend over the long term. Goldman Sachs highlights a potential investor question over whether PICC P&C itself might require capital: PICC P&C paid more than Rmb10bn in dividends to PICC Group in FY25 and reported a 214% core solvency ratio in 2Q26, versus peers at about 180%. The firm instead identifies the low-yield environment as a potential source of capital pressure at PICC Life and PICC Health, whose core solvency ratios declined by 86 and 77 percentage points, respectively, between 4Q24 and 2Q26. For PICC Group, Goldman Sachs remains Buy-rated on the H shares and Sell-rated on the A shares. Its 12-month SOTP-based targets are HK$7.0 for the H shares and Rmb6.4 for the A shares, implying 0.7x and 0.8x FY27E P/B, respectively. The valuation assigns PICC P&C 1.2x/1.3x FY27E P/B for H/A shares, based on 12.5% FY27E ROE, while PICC Life and PICC Health are valued at 0.5x/0.3x FY27E P/B based on Goldman Sachs’ ROA projections.

Analysis framework

Goldman Sachs first compares the announced support with prior reports and the insurers’ FY25 net assets, then traces the expected approval process and use of proceeds. It assesses PICC Group’s dilution, solvency and dividend implications, contrasts capital conditions across its operating businesses, and applies a sum-of-the-parts valuation using P/B multiples tied to projected ROE and ROA.

Methodology notes

• Valuation methodsSOTP (Sum-of-the-Parts) Valuation

  Sum-of-the-parts valuation for PICC Group

  Goldman Sachs values PICC P&C separately from PICC Life and PICC Health, then combines those business valuations into target prices for PICC Group’s H and A shares.

• Valuation methodsPB valuation

  Forward price-to-book valuation multiples

  The report applies FY27E P/B multiples to the operating businesses, with the selected multiples linked to projected ROE for PICC P&C and ROA projections for the life and health businesses.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• PICC Group H shares (1339.HK)

  The Rmb15bn capital raise could strengthen solvency capital, but the report identifies underwriting, catastrophe, investment, rates and dividend risks.

  Strengths

  Additional equity could improve core and comprehensive solvency capital by 6pt; PICC P&C paid more than Rmb10bn upstream in FY25 and had a 214% core solvency ratio in 2Q26.

  Weaknesses

  PICC Life and PICC Health experienced 86pt and 77pt core-solvency-ratio declines between 4Q24 and 2Q26 amid the low-yield environment.

  Comparison

  PICC P&C’s 214% core solvency ratio compares with peers’ average of about 180%.

  Risks

  Underwriting shortfalls, larger catastrophe losses, lower long-term yields, asset impairments and slower DPS growth are cited downside risks.

• PICC Group A shares (601319.SS)

  Goldman Sachs’ valuation incorporates the proposed capital strengthening and operating-business values.

  Strengths

  A higher PICC P&C dividend payout, improved life and health operations, or a meaningful recovery in long-term yields could support outcomes.

  Comparison

  The report values PICC P&C at 1.3x FY27E P/B for A shares versus 1.2x for H shares, and PICC Life/PICC Health at 0.3x versus 0.5x.

Key data

• Total MOF capital supportUp to Rmb70bnSupport announced for five centrally controlled insurers.
• Support relative to net assets5.6%Average of the five insurers’ FY25 net asset position.
• PICC Group planned capital raiseUp to Rmb15bnNew A-shares to be issued to the MOF.
• Estimated PICC new shares2.02bn shares / c.4.6% of outstanding sharesBased on the average trading price over the 20 trading days before the announcement.
• PICC solvency-capital improvement6ptEstimated improvement in both core and comprehensive solvency capital from Rmb15bn of additional equity.
• PICC P&C core solvency ratio214%As of 2Q26, versus peers’ average of about 180%.
• PICC P&C FY25 dividend to PICC GroupMore than Rmb10bnPotentially relevant to upstream capital and group dividends.
• PICC Group targetsHK$7.0 H shares / Rmb6.4 A shares12-month SOTP-based targets implying 0.7x/0.8x FY27E P/B.

Impact & implications

Goldman Sachs views the announcement as evidence of policy backing for the insurance industry. For PICC Group, the proposed raise is intended to strengthen capital and support operations, while investors are likely to focus on the approval process, dilution, capital needs in the life and health businesses, and the sustainability of dividend growth.

Risks

• For PICC Group H shares, underwriting results could fall below expectations or catastrophe-related losses could be larger than expected.
• Further declines in long-term bond yields could reduce the ROA outlook and book value of the life and health businesses and materially reduce their core solvency ratios.
• Higher investment-asset impairment losses and lower-than-expected DPS growth in a lower-for-longer rate environment are cited downside risks.

What to watch

• Whether PICC Group and China Re obtain shareholder approval at expected end-September EGMs and subsequent NFRA and CSRC approvals.
• Potential capital needs at PICC Life and PICC Health under a continuing low-yield environment.
• PICC P&C dividend payouts and resulting capital upstream to PICC Group.
• Long-term bond-yield movements and operating performance at PICC’s life and health businesses.